Drug Type Immune stimulating antibody conjugate (ISAC) |
Synonyms HER2 TriKE |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), IL-15 replacements(Interleukin-15 replacements), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | US | - | |
Gastrointestinal Neoplasms | Preclinical | US | - |